Microbiota in Rosacea

Rosacea is a chronic inflammatory skin disease affecting the central face. It was first described medically in the 14th century by Dr. Guy de Chauliac, a French surgeon [1]. The reported prevalence of rosacea is quite high and varies considerably between study populations [2] and geographical areas [3]. Rosacea is reported less frequently in people with highly pigmented skin than in those with a fair complexion, which is likely due to under-detection of the disease in individuals with a dark skin tone [3]. In a recent meta-analysis of studies of the general population (N = 26,519,836 individuals) and dermatology outpatients (N = 18,483), the pooled proportion of subjects with rosacea was 5.46% (estimated range 0.09–22.41%) in the general adult population and 2.39% (estimated range 0.00–23.14%) among dermatology outpatients [4]. Based on these findings, the National Rosacea Society (NRS) estimates that 415 million people suffer from rosacea worldwide [5]. Adults of 45–60 years of age are primarily affected, with no significant difference between women and men [4].

Although the pathophysiology of rosacea is poorly understood, the efficacy of antibiotics in rosacea treatment suggests that microbes are a pathogenic factor. All microorganisms (bacteria, viruses, fungi, and mites) present in/on the skin constitute the skin microbiota, including resident microorganisms (the core microbiota), which are symbionts, and transient microorganisms (the ‘tourists’), which arise from the environment and persist for hours to days before disappearing [6]. The microbiota acts as a barrier and has a protective role in the skin. Its composition depends on several factors, including skin pH, temperature, lipid composition, and humidity [7], as well as sex, age ([6, 7] and Luna [43] in this journal issue), stress, ethnicity [6], and environment (air pollution, detergents, cosmetics, etc. [7]; Callewaert et al. [44] in this journal issue). Ethnicity is thought to be less important than the local human body environment (sebaceous, dry, or moist) in determining cutaneous microbiota composition [8]. Under normal conditions, both the resident and transient microorganisms are nonpathogenic, and a balance is reached [6]. If this balance is altered, dysbiosis occurs and may aggravate skin diseases [6, 9].

Thanks to genomic advances, microbial research in many different disciplines has exploded in recent years [10]. Historically, bacteria from the human microbiota were studied using a culture-based approach. However, this method only allowed the identification of bacteria that could grow under standard laboratory conditions, therefore underestimating the microbial diversity of human-associated microbiota [10]. Analyses of complex microbial communities at the taxonomic and phylogenetic levels are now possible through the sequencing of bacteria-specific small subunit ribosomal RNAs (16S rRNAs) [10]. Compared with traditional culture-based methods, these molecular analyses have allowed the greater bacterial diversity on the human skin to be uncovered [11]. Corynebacteria, Propionibacteria (both Actinobacteria), and Staphylococci (Firmicutes) are the three most common genera identified in healthy subjects [11]. Microorganisms other than bacteria, such as Malassezia (a polymorphic yeast) and Demodex (a parasitic arthropod), are also found on healthy skin [6]. Both symbiotic microbiota (i.e., Demodex folliculorum and Staphylococcus epidermidis) and potentially pathogenic agents (i.e., Helicobacter pylori, Bacillus oleronius, and Chlamydia pneumoniae) are implicated in rosacea, although their precise roles remain unclear [9, 12].

After a short summary of the current knowledge on rosacea, this review discusses the role of the skin and gut microbiota in the pathophysiology of this disease. With this aim, a PubMed search of the English language literature was performed on January 31, 2020 and updated on May 30, 2020, without any limits on date of publication. Search terms included “rosacea,” “microbiome,” “microbiota,” “skin,” “gut,” and “antibiotics.”

Several studies [18‐20] recently used the microbial 16S rRNA polymerase chain reaction (PCR) amplification and sequencing technique to assess potential differences in the skin microbiota between patients with rosacea and healthy controls (Table 1). In a comparative study performed in 60 twins discordant for rosacea [18], the four most abundant phyla retrieved from the facial skin (assessed as the relative mean percentage abundance) were Firmicutes (42.98%), Proteobacteria (39.29%), Actinobacteria (15.88%) and Bacteroidetes (1.04%). No significant difference in the mean abundance of phyla was observed between groups of individuals with or without rosacea, or between different areas of the face [18]. In contrast, significant differences in skin microbiota were identified in a case–control observational study comparing 19 patients with mild-to-moderate rosacea (ETR, PPR, or both) with 19 matched healthy subjects [19]. Compared with healthy subjects, six species were depleted in ETR patients, and five species were enriched and six depleted in PPR patients. Despite these differences, Cutibacterium acnes (formerly called Propionibacterium acnes) was the most abundant species in all subjects [19]. In another study, in which the microbiota of Demodex mites were examined, C. acnes was also the predominant species in both ETR and PPR patients, and in sex- and age-matched healthy subjects [20]. Five other species (S. epidermidis, Corynebacterium kroppenstedtii, Streptococcus mitis, Cutibacterium granulosum and Snodgrassella alvi) were common to all subjects, but 72 species were only retrieved from the skin biopsies of patients with rosacea (with 37 and 31 species being specific to ETR and PPR, respectively) [20]. This study also found that the proportions of Proteobacteria and Firmicutes were higher in the PPR group compared with the ETR and control groups, whereas the proportion of Actinobacteria was lower in the PPR group than in the ETR and control groups [20]. Interestingly, B. oleronius was not identified in this study, even though this bacterium was suggested to be involved in rosacea after it was cultured from a D. folliculorum mite of a patient with PPR [21].

Thus, the comparative studies conducted so far have produced discordant results concerning the differences in the overall microbiota composition between rosacea patients and healthy subjects and the type of bacteria potentially involved in rosacea. These differences may be due to disparities in patient age, ethnicity, environment, and geographical location, as such factors are known to affect skin microbiota composition.

Pattern recognition receptors (PRRs) expressed on the skin participate in a continuous immune surveillance that allows symbiont microorganisms to thrive while eliminating potential pathogens [6, 9]. Two of these PRRs—TLR-2 and nucleotide-binding oligomerization domain (NOD)-like receptor family, pyrin domain-containing 3 (NLRP3, also called NALP3)—are upregulated in rosacea patients, and their activation by Demodex mites are thought to trigger inflammation in rosacea (summarized in Fig. 3) [2, 9, 12]. Indeed, chitin (from the mite exoskeleton) can stimulate the pro-inflammatory response of keratinocytes through TLR-2 [12], and mite allergens have been shown to activate NOD-like receptors in vitro [9]. Microbiota residing on Demodex mites may also be involved in this process: antigens from B. oleronius reportedly induced the proliferation of peripheral blood mononuclear cells from rosacea patients [21], and stimulated the production of cathelicidin, MMP-9, tumor necrosis factor (TNF) and interleukin (IL)-8 by neutrophils from healthy subjects [9, 12]. In patients with rosacea, this inflammatory state causes an increase in the facial skin temperature [28]. This in turn can affect microbiota growth and balance [9], and modify the behavior of S. epidermidis so that it secretes more proteins [28] (see Sect. 4.4). Moreover, as S. epidermidis antigens are recognized by TLR-2, the bacterium also participates in skin inflammation [12].

Unlike in acne, C. acnes does not seem to play a major role in the pathogenesis of rosacea [29]. In fact, here C. acnes is suspected to have a protective effect in healthy skin by breaking down sebum into free fatty acids (FFAs), which can prevent the growth of pathogens [30].

Patients with rosacea may have systemic comorbidities, including diseases of the gastrointestinal tract (e.g., gastroesophageal reflux disease, gastritis, Crohn’s disease, ulcerative colitis, celiac disease, and small intestinal bacterial overgrowth [SIBO] syndrome), suggesting a link between rosacea and the gut [31‐33]. Furthermore, the gut microbiota has been shown to influence skin homeostasis: either directly in case of intestinal barrier disruption, or indirectly through the modulation of systemic immunity or by generating short-chain fatty acids [7]. The gut is inhabited by a huge number of microorganisms (> 10¹⁴) constituting the gut microbiota, and several factors including the mode of birth, food, age, stress, and antibiotics may affect its composition and may therefore trigger rosacea [34]. Another argument is the positive effect of oral probiotics observed in patients with rosacea. In a randomized, controlled, non-blinded trial, patients with papulopustular exanthema (including 36% with rosacea) who received the bacteria Escherichia coli Nissle 1917 as an oral probiotic as well as a standard topical therapy had a better outcome than patients who only received the standard treatment (P < 0.01) [35]. Fortuna et al. [36] also reported a case of rosacea with scalp involvement that was successfully treated with low-dose doxycycline (40 mg/day) combined with oral probiotics (Bifidobacterium breve BR03 and Lactobacillus salivarius LS01) for 8 weeks, followed by probiotics alone. No relapse or flare-up of disease was observed during 6 months of follow-up [36]. However, the mechanisms underlying the involvement of gut bacteria in rosacea pathophysiology have not yet been elucidated. Although studies have failed to confirm an association between H. pylori and rosacea, antibodies against cytotoxin-associated gene A (CagA), an H. pylori virulent factor, have been identified in most patients with rosacea [9, 12]. The gut microbiota in rosacea patients was recently investigated in two Asian metagenomic studies [37, 38]. In the study by Nam et al. [37] performed in Korean women (12 rosacea patients and 251 controls), bacteria from the Peptococcaceae family and the Methanobrevibacter genus were detected in control subjects but not in rosacea patients, whereas bacteria from the Acidaminococcus and Megasphaera genera were significantly more abundant in rosacea patients than in controls [37]. In contrast, Chen et al. [38] observed a lower abundance of Acidaminococcus and Megasphaera genera in Taiwanese subjects (11 rosacea patients and 110 controls, 90.9% women). Lactobacillus, Hemophilus, Roseburia, and Clostridium genera were also less abundant in rosacea patients than in controls, whereas Rhabdochlamydia, CF231, Bifidobacterium, Sarcina, and Ruminococcus genera were significantly more abundant [38]. Therefore, differences between rosacea patients and healthy subjects were observed in both studies, although the results were discordant. Further studies with higher numbers of rosacea patients are required. As rosacea is induced or aggravated by emotional stress [2], it is likely that the brain is involved in cross-talk between the skin and gut microbiota in rosacea, as in acne, through the gut-brain-skin axis (Fig. 4) [7, 9, 39‐42].

The 16s rRNA studies highlighted in this review suggest a link between the skin and gut microbiota and rosacea; however, the role of these microorganisms in the disease pathophysiology is yet to be determined. With limited data, it is not known whether dysbiosis and altered microbiota metabolism are potentiators of inflammation or secondary outcomes in response to changes in the skin microenvironment. Microbial 16S rRNA PCR amplification and sequencing have enabled us to analyze complex microbial communities at the taxonomic and phylogenetic levels. However, to our disappointment, results from microbial studies in rosacea patients have so far been discordant at the level of both the skin [18‐20] and the gut [37, 38]. It is especially difficult to interpret the findings from these studies because skin and gut microbial composition depends on numerous factors, including food, age, stress, and environment. There are also great interpersonal differences in the human microbiota, a problem that can only be overcome by conducting studies using paired samples from the same patient [22]. Although data are scarce, the reports of successful rosacea treatment with oral probiotics combined with conventional therapy are promising [35, 36] and provide evidence for the role of the gut microbiota in rosacea pathogenesis. In acne, several clinical trials reported positive results with oral or topical probiotics used alone or in combination. Further investigations are necessary to assess the efficacy of oral/topical probiotics and/or prebiotics in rosacea and identify their exact mechanisms of action. We should be aware that such treatments may require customization due to great interpersonal differences in the skin and gut microbiota. Moreover, as food affects gut microbiota composition [34], further research in this domain could lead to adapted dietary advice being provided to patients with rosacea.

Another exciting field of research is investigation of the gut-brain-skin axis in rosacea; a greater understanding of how the brain (i.e., stress) influences the gut and skin microbiota could also provide better therapeutic strategies (i.e., stress-relieving practices).